A biopsy is a small operation that is used to perform the removal of tissues from an area of concern from the body. Breast biopsy is a medical procedure that involves the testing of small samples of breast tissues for the detection of breast cancer. This form of biopsy is conducted with the help of minimally invasive biopsy systems due to minimal pain and disfigurement. There are various types of biopsy procedures that are used depending upon the different techniques like vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). These are recommended by the doctor based on the size, location, and other characteristics of the breast abnormality. The global breast biopsy market is expected to expand in significant fashion during the forecast period of 2018 to 2023.
Latest Free Sample PDF Available @ https://www.marketresearchfuture.com/sample_request/6288
The increasing prevalence of breast cancer, especially for women above 35 years of age during menopause, who are more susceptible to breast cancer, and rising awareness concerning breast cancer screening programs are the major drivers of the market. However, there are various constraints limiting the market growth as well. This includes the infection risks associated with breast biopsy procedures, unspecified regulatory issues, and ambiguous reimbursement policies. In addition to these, the market growth is also restricted due to the high cost of surgical procedures and the risks associated with them. At the same time, the emergence of technologically-advanced and the usage of breast biopsy devices that are minimally invasive are expected to tap into the potential opportunities that the market holds.
The global breast biopsy market statistics is segmented on the basis of type, application, and end user.
On the basis of type, market is segmented into PET, mammography, CT, MRI, breast biopsy, tactile imaging, ultrasound, and others. Mammography is further segmented into 3D mammography, film-screen mammography, Full-field digital mammography (FFDM), scintimammography or molecular breast imaging, and others. Breast biopsy is further segmented into ultrasound-guided core biopsy, image-guided breast biopsy, tactic core biopsy, and others.
On the basis of application, the market is segmented into metastatic axillary adenocarcinoma, breast cancer diagnosis, post-neoadjuvant chemotherapy, and others.
On the basis of end user, the market is segmented into diagnostic centers, hospitals, and others.
The regional analysis of the breast biopsy market observes that the North American region is projected to account for the principal market share owing to the early implementation of sophisticated medical technologies and constant development by companies working in cancer diagnostics. The breast biopsy market is mainly focused on the North American and European regions, which is expected to account for more than 50% of the market portion. The European market is estimated to hold the next biggest market share as breast cancer is found to be most common in countries such as the UK and Belgium. The market share in the Asia Pacific region is also estimated to experience growth in the near future due to access to optimal treatment facilities, better adoption rate, growing demand for advanced technology, growing government initiatives, and rising healthcare costs. The market in the Middle Eastern and African region is projected to be responsible for the smallest share of the breast biopsy market owing to deficiency of technical knowledge, an underdeveloped healthcare sector, and meager medical facilities.
The global breast biopsy market includes a number of leading market players, including Cook Medical Incorporated, Dickinson and Company, NuVue Therapeutics, Argon Medical Devices, Inc., Johnson & Johnson, Encapsule Medical Devices LLC., Leica Biosystems, C.R. Bard Inc., Argon Medical Devices, Hologic Inc., Devicor Medical Products Inc., Becton, Hologic Inc., Karl Storz GmbH & Co. Kg, GE Healthcare., Intact Medical Corporation, Conceptus INC, and Galini SRL.
October 30th, 2019, a team from ETH Zurich with support from the Swiss National Science Foundation developed a new ultrasound method to help differentiate benign breast tumors from the malignant ones. The clinical trials have proven to show great promise in the detection of breast cancer and can be revolutionary in the medical segment for detecting breast cancer.
LIST OF TABLES
Table 1 Breast Biopsy Market Industry Synopsis, 2018–2023
Table 2 Global Breast Biopsy Market Estimates & Forecast, 2018–2023, (USD Million)
Table 3 Global Breast Biopsy Market, by Region, 2018–2023, (USD Million)
Table 4 Global Breast Biopsy Market, by Diagnosis, 2018–2023, (USD Million)
Table 5 Global Breast Biopsy Market, by Treatment, 2018–2023, (USD Million)
Browse Complete Report @ https://www.marketresearchfuture.com/reports/breast-biopsy-market-6288
Related Reports Links:-
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half- Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312
Email: [email protected]